Nuformix plc (LSE:NFX) — Market Cap & Net Worth
Market Cap & Net Worth: Nuformix plc (NFX)
Nuformix plc (LSE:NFX) has a market capitalization of $43.64K (GBX358.66 Million) as of May 3, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31143 globally and #1213 in its home market, demonstrating a -5.56% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nuformix plc's stock price GBX0.17 by its total outstanding shares 2109749903 (2.11 Billion). Analyse cash efficiency ratio of Nuformix plc to see how efficiently the company converts income to cash.
Nuformix plc Market Cap History: 2015 to 2026
Nuformix plc's market capitalization history from 2015 to 2026. Data shows change from $577.56K to $43.64K (-23.18% CAGR).
Nuformix plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nuformix plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.75x
Nuformix plc's market cap is 1.75 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $539.06K | $15.00K | -$1.84 Million | 35.94x | N/A |
| 2019 | $2.30 Million | $610.00K | -$1.66 Million | 3.77x | N/A |
| 2020 | $693.08K | $535.00K | -$756.38K | 1.30x | N/A |
| 2021 | $275.95K | $195.55K | -$1.25 Million | 1.41x | N/A |
| 2022 | $87.28K | $50.00K | -$1.11 Million | 1.75x | N/A |
Competitor Companies of NFX by Market Capitalization
Companies near Nuformix plc in the global market cap rankings as of May 3, 2026.
Key companies related to Nuformix plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Nuformix plc Historical Marketcap From 2015 to 2026
Between 2015 and today, Nuformix plc's market cap moved from $577.56K to $ 43.64K, with a yearly change of -23.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX43.64K | -33.33% |
| 2025 | GBX65.46K | +436.84% |
| 2024 | GBX12.19K | -85.38% |
| 2023 | GBX83.43K | -4.41% |
| 2022 | GBX87.28K | -68.37% |
| 2021 | GBX275.95K | -60.19% |
| 2020 | GBX693.08K | -69.83% |
| 2019 | GBX2.30 Million | +326.19% |
| 2018 | GBX539.06K | -30.00% |
| 2017 | GBX770.09K | -14.29% |
| 2016 | GBX898.43K | +55.56% |
| 2015 | GBX577.56K | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Nuformix plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $43.64K USD |
| MoneyControl | $43.64K USD |
| MarketWatch | $43.64K USD |
| marketcap.company | $43.64K USD |
| Reuters | $43.64K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nuformix plc
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis… Read more